BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hong W, Zhao M, Li H, Peng F, Wang F, Li N, Xiang H, Su Y, Huang Y, Zhang S, Zhao G, Zhou R, Mao L, Lin Z, Fang Y, Zhang Q, Xie B. Higher Plasma S100B Concentrations in Schizophrenia Patients, and Dependently Associated with Inflammatory Markers. Sci Rep 2016;6:27584. [PMID: 27279465 DOI: 10.1038/srep27584] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Cai H, Zeng C, Zhang X, Liu Y, Wu R, Guo W, Wang J, Wu H, Tang H, Ge X, Yu Y, Zhang S, Cao T, Li N, Liang X, Yang P, Zhang B. Diminished treatment response in relapsed versus first-episode schizophrenia as revealed by a panel of blood-based biomarkers: A combined cross-sectional and longitudinal study. Psychiatry Res 2022;316:114762. [PMID: 35940088 DOI: 10.1016/j.psychres.2022.114762] [Reference Citation Analysis]
2 Huang Z, Kang M, Li G, Xiong P, Chen H, Kang L, Li S, Lu C, Li Q, Bai M. Predictive effect of Bayes discrimination in the level of serum protein factors and cognitive dysfunction in schizophrenia. Journal of Psychiatric Research 2022;151:539-45. [DOI: 10.1016/j.jpsychires.2022.05.004] [Reference Citation Analysis]
3 Ma H, Cheng N, Zhang C. Schizophrenia and Alarmins. Medicina (Kaunas) 2022;58:694. [PMID: 35743957 DOI: 10.3390/medicina58060694] [Reference Citation Analysis]
4 Janigro D, Mondello S, Posti JP, Unden J. GFAP and S100B: What You Always Wanted to Know and Never Dared to Ask. Front Neurol 2022;13:835597. [PMID: 35386417 DOI: 10.3389/fneur.2022.835597] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
5 Kozłowska E, Brzezińska-Błaszczyk E, Agier J, Wysokiński A, Żelechowska P. Alarmins (IL-33, sST2, HMGB1, and S100B) as potential biomarkers for schizophrenia. J Psychiatr Res 2021;138:380-7. [PMID: 33957300 DOI: 10.1016/j.jpsychires.2021.04.019] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
6 Javelle F, Bloch W, Knoop A, Guillemin GJ, Zimmer P. Toward a neuroprotective shift: Eight weeks of high intensity interval training reduces the neurotoxic kynurenine activity concurrently to impulsivity in emotionally impulsive humans - A randomized controlled trial. Brain Behav Immun 2021;96:7-17. [PMID: 33932526 DOI: 10.1016/j.bbi.2021.04.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
7 Langeh U, Singh S. Targeting S100B Protein as a Surrogate Biomarker and its Role in Various Neurological Disorders. Curr Neuropharmacol 2021;19:265-77. [PMID: 32727332 DOI: 10.2174/1570159X18666200729100427] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
8 Futtrup J, Margolinsky R, Benros ME, Moos T, Routhe LJ, Rungby J, Krogh J. Blood-brain barrier pathology in patients with severe mental disorders: a systematic review and meta-analysis of biomarkers in case-control studies. Brain Behav Immun Health 2020;6:100102. [PMID: 34589864 DOI: 10.1016/j.bbih.2020.100102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
9 Mongan D, Sabherwal S, Susai SR, Föcking M, Cannon M, Cotter DR. Peripheral complement proteins in schizophrenia: A systematic review and meta-analysis of serological studies. Schizophr Res 2020;222:58-72. [PMID: 32456884 DOI: 10.1016/j.schres.2020.05.036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
10 Momtazmanesh S, Zare-Shahabadi A, Rezaei N. Cytokine Alterations in Schizophrenia: An Updated Review. Front Psychiatry 2019;10:892. [PMID: 31908647 DOI: 10.3389/fpsyt.2019.00892] [Cited by in Crossref: 49] [Cited by in F6Publishing: 82] [Article Influence: 16.3] [Reference Citation Analysis]
11 Tat RM, Golea A, Vesa ŞC, Ionescu D. Determination of Cut-off Serum Values for Resistin and S100B Protein in Patients Who Survived a Cardiac Arrest. J Crit Care Med (Targu Mures) 2019;5:97-102. [PMID: 31431922 DOI: 10.2478/jccm-2019-0018] [Reference Citation Analysis]
12 Mongan D, Ramesar M, Föcking M, Cannon M, Cotter D. Role of inflammation in the pathogenesis of schizophrenia: A review of the evidence, proposed mechanisms and implications for treatment. Early Interv Psychiatry 2020;14:385-97. [PMID: 31368253 DOI: 10.1111/eip.12859] [Cited by in Crossref: 19] [Cited by in F6Publishing: 28] [Article Influence: 6.3] [Reference Citation Analysis]
13 Trovão N, Prata J, VonDoellinger O, Santos S, Barbosa M, Coelho R. Peripheral Biomarkers for First-Episode Psychosis-Opportunities from the Neuroinflammatory Hypothesis of Schizophrenia. Psychiatry Investig 2019;16:177-84. [PMID: 30836740 DOI: 10.30773/pi.2018.12.19.1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
14 Morera-Fumero AL, Díaz-Mesa E, Abreu-Gonzalez P, Fernandez-Lopez L, Cejas-Mendez MDR. Day/night changes in serum S100B protein concentrations in acute paranoid schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2017;75:207-12. [PMID: 28188811 DOI: 10.1016/j.pnpbp.2017.02.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]